The biotech mailbag: Your questions answered on Clovis Oncology, CytRx, Brainstorm Therapeutics, and more
Columnist Adam Feuerstein answers your question on biotech stocks and clinical trials in oncology, ALS, iron replacement therapy, and more.
The Biotech Stock Mailbag has a new home. Here’s what readers are saying:
Steve N. writes, “I don’t understand why people are selling Clovis Oncology on this news of a partnership with Bristol-Myers Squibb? Can you explain what I am missing here?”
Clovis, which fell 14 percent Monday, got caught up in one of those counter-intuitive, only-on-Wall-Street situations where good news is treated like bad news because it’s not the good news people expected.
The news reported Monday: Clovis and Bristol are pairing up to conduct combination studies of Rubraca (Clovis’ and Opdivo (Bristol’s checkpoint inhibitor) in ovarian cancer, triple-negative breast cancer, and prostate cancers. Financial terms were not disclosed but this appears to
